Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ark Therapeutics Treats First Patient In Phase I/IIa Refractory Angina Trial
The company reported that the patient was given a single dose of 1 X 109 viral particles of Ad-VEGF-D and has been moved from post operative critical care
The company reported that the patient was given a single dose of 1 X 109 viral particles of Ad-VEGF-D and has been moved from post operative critical care
On 11 January, ReNeuron announced that it finalised and submitted the supplemental pre-clinical data package requested by the UK Gene Therapy Advisory Committee (GTAC), in support of the
With the EC approval, Merck also receives marketing authorization for Elonva with unified labeling valid in all the EU member states. Elonva is a sustained follicle stimulant capable
The ‘Hub for Translational Medicine’ aims to enhance the understanding of how scientific advances from preclinical research can be transferred in practice to patients. Bringing together world-class expertise
The approval is based on the positive results from the international ToGA trial, which showed that treatment with Herceptin prolongs the lives of patients with this aggressive cancer.
Research and development across Atlantic Canada is benefiting from an important federal investment of $62.4m, under Round VII of the Atlantic Innovation Fund (AIF). Reportedly, in the island,
The company said that Livea mimics the body’s natural signaling process making the body feel full, leading to weight loss. As the proprietary blend of ingredients is all-natural,
In the Phase 1 trial, IMO-3100 is being administered by subcutaneous injection to healthy subjects in a rising single-dose design. The primary objective is to evaluate safety and
CFP is expected to sell Capran 1200, 1500, 1500M, 2500 and 2500M. These films are manufactured at Honeywell’s Pottsville plant in Pennsylvania. The company claims that Capran films
The company said that the Nasal spray ZT-034 is being developed as an alternative to Eli Lilly’s Forteo (teriparatide [rDNA origin]), for the treatment of osteoporosis, and is